GLP-1s or obesity drugs are growing in popularity. What does this mean for sectors ranging from biotech to insurance and food?| www.jpmorgan.com
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.| jamanetwork.com
Vox’s coverage of all things health, including personal health, public health, mental health, and more.| Vox
See facts and figures on overdose deaths as reported by the U.S. Centers for Disease Control and Prevention| National Institute on Drug Abuse